受体介导靶向恶性脑胶质瘤递药系统研究进展.pdfVIP

Pharmacy Information 药物资讯, 2018, 7(2), 27-32 Published Online March 2018 in Hans. /journal/pi /10.12677/pi.2018.72006 Research Progress in Malignant Glioma Targeting Delivery System Mediated with Receptors Hongyan Wang, Yu Liu* China Pharmaceutical University, Nanjing Jiangsu th nd th Received: Mar. 10 , 2018; accepted: Mar. 22 , 2018; published: Mar. 29 , 2018 Abstract The worldwide cancer incidence of malignant encephalic glioma is 3.20/100,000, the median sur- vival for patients is less than 2 years and 9.8% of patients survived five years post diagnosis, with near 100% relapse rates and currently limited treatment options. Operations and chemotherapy drugs have limited efficacy for aggressive glioma with intrinsic resistance to drugs. Almost the whole of macromolecule and 98% of small-molecule drugs are unable to across blood-brain bar- rier. The receptor mediated endocytosis is one of the endogenous transporting channels, xenobio- tics across blood-brain barrier and target glioma by taking advantages of cells. It provides a safer and more effective drugs delivery strategy for cancer treatment. Keywords Malignant Glioma, Blood-Brain Barrier, Receptor, Targeting Drugs Delivery 受体介导靶向恶性脑胶质瘤递药系统的研究进展 汪红艳，刘 煜* 中国药科大学，江苏 南京 收稿日期：2018年3月10 日；录用日期：2018年3月22 日；发布日期：2018年3月29 日 摘 要 恶性脑胶质瘤全球发病率为3.20/100,000，患者中位生存期不足2年，5年生存率仅9.8%，治疗后复发 *通讯作者。 文章引用: 汪红艳, 刘煜. 受体介导靶向恶性脑胶质瘤递药系统的研究进展[J]. 药物资讯, 2018, 7(2): 27-32. DOI: 10.12677/pi.2018.72006 汪红艳，刘煜 率几近100%，且目前仍无有效治疗方案。由于恶性胶质瘤存在浸润性生长的特点，手术无法根治，对 于常用化疗药物又普遍存在内在抗拒性，导致化疗疗效有限。由于血脑屏障的存在，几乎全部的大分子 药物以及98% 以上的小分子药物都无法到达病灶，而受体介导的转运方式利用了血脑屏障自身的特性， 通过内源性血脑屏障转运系统有效的跨越血脑屏障并靶向恶性胶质瘤进行药物输送，为胶质瘤的治疗提 供了一种更为安全且有效的递药策